ClinicalTrials.gg

Program

lirafugratinib

Also written as “Lirafugratinib” and “RLY-4008”.

Its studies are mostly in Cholangiocarcinoma, led by Elevar Therapeutics.

Furthest: phase 2, since Aug 7, 20202 company-led studies, 1 open or runningNext primary completion: Sep 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Elevar Therapeutics21 open or runningphase 2since Aug 7, 2020Aug 7, 2020Sep 2027phase 2 · NCT07359820

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 7, 2020First study: phase 2 study in CholangiocarcinomaFirst studyNCT04526106 · 490 enrolled · United States, Australia, France and more
  2. Jan 16, 2026Phase 2 study in FGFR2 Gene Fusion/RearrangementNCT07359820 · 30 planned · United States, France, South Korea and more

Ahead

  1. Sep 2027Primary completion: phase 2 study in FGFR2 Gene Fusion/RearrangementNCT07359820

TargetBeta

FGFR2 →read by rule
“An orally bioavailable inhibitor of the fibroblast growth factor receptor 2 (FGFR2), ”NCIt, by rule

Other programs on FGFR2

ProgramCompanyFurthest phaseStudies
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
infigratinibruleBridgeBiophase 317
pemigatinibruleIncytephase 316
futibatinibruleOtsukaphase 310
FGFR2/3 Inhibitor CGT4859rulecogent-biosciences-incphase 21
KNT-0916rulekinoteck-therapeutics-co-ltdphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07359820FGFR2 Gene Fusion/Rearrangement · United States, France, South Korea and more2RecruitingSep 202730
NCT04526106Cholangiocarcinoma · United States, Australia, France and more2CompletedSep 5, 2025490

How it is read

Names in the registry

  • “Lirafugratinib”, 1 entry
  • “RLY-4008”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.